Get the Stockscreener App
2.32
7.91%
0.17
After Hours:
2.35
0.03
+1.29%
Polaryx Therapeutics Inc stock is traded at $2.32, with a volume of 194.07K.
It is up +7.91% in the last 24 hours and down -12.78% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
See More
Previous Close:
$2.15
Open:
$2.39
24h Volume:
194.07K
Relative Volume:
0.99
Market Cap:
$115.64M
Revenue:
-
Net Income/Loss:
$-6.48M
P/E Ratio:
-16.93
EPS:
-0.137
Net Cash Flow:
$-5.30M
1W Performance:
+13.17%
1M Performance:
-12.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.05
$2.39
1-Week Range:
$1.86
$2.39
52-Week Range:
$1.86
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
201-940-7236
Address
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.32 | 97.70M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Initiated | Maxim Group | Buy |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Se - GuruFocus
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy - GuruFocus
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com Canada
PLYX|Polaryx Therapeutics Ord Shs|Price:1.950|Chg%:-0.100 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – NASDAQ:PLYX - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PLYX|Polaryx Therapeutics Ord Shs|Price:2.050|Chg%:-0.060 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX - TradingView
Polaryx Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
Polaryx Therapeutics, Inc. Files Form 8-K as Emerging Growth Company on NASDAQ (PLYX) – July 2026 - Minichart
Polaryx Therapeutics' Lisa Bollinger resigns as Chief Medical Officer - TradingView
Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026 - marketscreener.com
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis - Kalkine
Polaryx Sets 2026 Virtual Annual Shareholder Meeting - TipRanks
Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline - Stock Titan
Polaryx Therapeutics sets 2026 annual shareholder meeting as virtual event - Bitget
Polaryx Therapeutics (PLYX) Edges Higher Amidst Narrow Trading RangeMedian Line - dars.gov.et
What is HC Wainwright's Forecast for PLYX Q2 Earnings? - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
PLYX News Today | Why did Polaryx Therapeutics stock drop today? - MarketBeat
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating - Investing.com
PLYX Initiates Coverage On Polaryx Therapeutics -- Price Target Set at $7.00 - GuruFocus
Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co. - Moomoo
Investment firm H.C. Wainwright announced today the launch of initial coverage research on biopharmaceutical company Polaryx Therapeutics Inc. - Bitget
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Operating cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Free cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Polaryx Therapeutics (PLYX) Surges 7.7%: Momentum Builds Above Key SupportInstitutional Sentiment - DonanımHaber
Polaryx Therapeutics (PLYX) Holds Steady Near Support as Technical Indicators Signal ConsolidationSector Sentiment - dars.gov.et
Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Enterprise value to revenue forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to sales forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to earnings forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX) - TradingView
PLYX Forecast — Price Target — Prediction for 2027 - TradingView
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Ord Shs (PLYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polaryx Therapeutics Ord Shs - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Institutional Confidence - TradingKey
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Polaryx Therapeutics (PLYX) Holds Steady Near Support Amid Quiet TradingPullback Trade - DonanımHaber
Polaryx Therapeutics (PLYX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Faces Pressure After 6.7% Drop: Key Support Levels in FocusHead and Shoulders - newsline.com
Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Polaryx Therapeutics (PLYX) Stock Chart and Price History 2026 - MarketBeat
Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock By Investing.com - Investing.com Australia
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polaryx Therapeutics Inc Stock (PLYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Landis G. Michael | Chief Financial Officer |
Feb 18 '26 |
Buy |
2.79 |
2,867 |
7,991 |
228,225 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):